Rangering i aksjer
#29740
Evaxion Biotech A/S is a clinical-stage biotechnology firm dedicated to... Evaxion Biotech A/S is a clinical-stage biotechnology firm dedicated to creating artificial intelligence-driven immunotherapies. Its innovative pipeline targets cancers, bacterial infections, and viral diseases. The company's oncology portfolio features several promising candidates: EVX-01, a leading cancer immunotherapy currently in Phase IIb clinical trials for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy undergoing Phase IIa trials for adjuvant melanoma; and EVX-03, another DNA-based immunotherapy in development for a range of cancers. Beyond oncology, Evaxion is advancing three pre-clinical vaccine candidates—EVX-B1, EVX-B2, and EVX-V1—aimed at combating various bacterial and viral pathogens. Founded in 2008, Evaxion Biotech A/S is headquartered in Hørsholm, Denmark.
Aksjekurs
$3.14
Sist synkronisert: 2026-08-18
Handel Evaxion Biotech A/S (EVAX)
Pris EVAX pris med markedsverdi på B
Markedsverdi av Evaxion Biotech A/S(EVAX)
Markedsverdi: $19.83M
Per August 2026 har Evaxion Biotech A/S en markedsverdi på $19.83M. Dette gjør Evaxion Biotech A/S til det 29740th mest verdifulle selskapet i verden basert på markedsverdi ifølge våre data. Markedsverdi er den totale markedsverdien av et børsnotert selskaps utestående aksjer og brukes vanligvis til å måle hvor mye et selskap er verdt.
Markedsverdihistorikk for Evaxion Biotech A/S fra 2021 til 2026
EVAX sammenlignet med topp 5 mest populære stocks
| Pris på EVAX |
|
Eiendel B |
Markedsverdi for B |
Resultater |
|
|
|
|
$5.307T
|
+26,754,815.74%
|
|
|
|
|
$4.551T
|
+22,943,949.74%
|
|
|
|
|
$4.154T
|
+20,945,524.83%
|
|
|
|
|
$3.589T
|
+18,092,768.75%
|
|
|
|
|
$2.797T
|
+14,101,147.13%
|
